Skip to contentB
BIO-TECHNE Corp
B
TECHBIO-TECHNE Corp Q4 2026 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$321.19M$321.19Mderived+1.3% vs Q4 2025 Net Income$54.62M$54.62MderivedN/M vs Q4 2025 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BIO-TECHNE Corp · CIK 842023 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$211,394,000+6.3% Operating Incomederived$74,276,000N/M Operating Cash Flowderived$95,416,000−2.8% Free Cash Flowderived$86,936,000−6.8% Margins · derivedGross margin65.8%+3.1 pt vs Q4 2025
Operating margin23.1%+30.7 pt vs Q4 2025
Net margin17.0%+22.6 pt vs Q4 2025
ended Jun 30, 2026 · filed Aug 24, 2026 · 55 d after period end